These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 17488796)

  • 1. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.
    Durante C; Puxeddu E; Ferretti E; Morisi R; Moretti S; Bruno R; Barbi F; Avenia N; Scipioni A; Verrienti A; Tosi E; Cavaliere A; Gulino A; Filetti S; Russo D
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2840-3. PubMed ID: 17488796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of iodine metabolism genes in human thyroid tissues: evidence for age and BRAFV600E mutation dependency.
    Espadinha C; Santos JR; Sobrinho LG; Bugalho MJ
    Clin Endocrinol (Oxf); 2009 Apr; 70(4):629-35. PubMed ID: 18710471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
    Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
    Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
    Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
    Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced expression of THRβ in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression.
    Rosignolo F; Maggisano V; Sponziello M; Celano M; Di Gioia CR; D'Agostino M; Giacomelli L; Verrienti A; Dima M; Pecce V; Durante C
    J Endocrinol Invest; 2015 Dec; 38(12):1283-9. PubMed ID: 26003825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene.
    Lin JD; Fu SS; Chen JY; Lee CH; Chau WK; Cheng CW; Wang YH; Lin YF; Fang WF; Tang KT
    Thyroid; 2016 May; 26(5):691-704. PubMed ID: 26914762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas.
    Durante C; Tallini G; Puxeddu E; Sponziello M; Moretti S; Ligorio C; Cavaliere A; Rhoden KJ; Verrienti A; Maranghi M; Giacomelli L; Russo D; Filetti S
    Eur J Endocrinol; 2011 Sep; 165(3):455-63. PubMed ID: 21653734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation.
    Franzoni A; Dima M; D'Agostino M; Puppin C; Fabbro D; Loreto CD; Pandolfi M; Puxeddu E; Moretti S; Celano M; Bruno R; Filetti S; Russo D; Damante G
    Thyroid; 2009 Mar; 19(3):247-55. PubMed ID: 19207009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake.
    Mian C; Barollo S; Pennelli G; Pavan N; Rugge M; Pelizzo MR; Mazzarotto R; Casara D; Nacamulli D; Mantero F; Opocher G; Busnardo B; Girelli ME
    Clin Endocrinol (Oxf); 2008 Jan; 68(1):108-16. PubMed ID: 17854396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postnatal expression of BRAFV600E does not induce thyroid cancer in mouse models of thyroid papillary carcinoma.
    Shimamura M; Nakahara M; Orim F; Kurashige T; Mitsutake N; Nakashima M; Kondo S; Yamada M; Taguchi R; Kimura S; Nagayama Y
    Endocrinology; 2013 Nov; 154(11):4423-30. PubMed ID: 23970782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
    Nicolussi A; D'Inzeo S; Mincione G; Buffone A; Di Marcantonio MC; Cotellese R; Cichella A; Capalbo C; Di Gioia C; Nardi F; Giannini G; Coppa A
    Int J Oncol; 2014 Feb; 44(2):548-56. PubMed ID: 24316730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes.
    Lazar V; Bidart JM; Caillou B; Mahé C; Lacroix L; Filetti S; Schlumberger M
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3228-34. PubMed ID: 10487692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF(V600E) mutation and the biology of papillary thyroid cancer.
    Frasca F; Nucera C; Pellegriti G; Gangemi P; Attard M; Stella M; Loda M; Vella V; Giordano C; Trimarchi F; Mazzon E; Belfiore A; Vigneri R
    Endocr Relat Cancer; 2008 Mar; 15(1):191-205. PubMed ID: 18310287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
    Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
    Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expressions of human sodium iodide symporter mRNA in primary and metastatic papillary thyroid carcinomas.
    Park HJ; Kim JY; Park KY; Gong G; Hong SJ; Ahn IM
    Thyroid; 2000 Mar; 10(3):211-7. PubMed ID: 10779135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer.
    Ringel MD; Anderson J; Souza SL; Burch HB; Tambascia M; Shriver CD; Tuttle RM
    Mod Pathol; 2001 Apr; 14(4):289-96. PubMed ID: 11301345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas.
    Puxeddu E; Moretti S; Elisei R; Romei C; Pascucci R; Martinelli M; Marino C; Avenia N; Rossi ED; Fadda G; Cavaliere A; Ribacchi R; Falorni A; Pontecorvi A; Pacini F; Pinchera A; Santeusanio F
    J Clin Endocrinol Metab; 2004 May; 89(5):2414-20. PubMed ID: 15126572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas.
    Yoon M; Jung SJ; Kim TH; Ha TK; Urm SH; Park JS; Lee SM; Bae SK
    Endocr Res; 2016; 41(1):64-9. PubMed ID: 26513490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas.
    Lee JH; Lee ES; Kim YS; Won NH; Chae YS
    Pathology; 2006 Jun; 38(3):201-4. PubMed ID: 16753739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.